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Abstract
 
In latently infected B lymphocytes, the Epstein-Barr virus (EBV) suppresses signal transduction
from the antigen receptor through expression of the integral latent membrane protein 2A
(LMP2A). At the same time, LMP2A triggers B cell survival by a yet uncharacterized mainte-
nance signal that is normally provided by the antigen receptor. The molecular mechanisms are
unknown as LMP2A-regulated signaling cascades have not been described so far. Using a novel
mouse model we have identified the intracellular adaptor protein Src homology 2 (SH2) do-
main–containing leukocyte protein (SLP)-65 as a critical downstream effector of LMP2A in
vivo. Biochemical analysis of the underlying signaling pathways revealed that EBV infection
causes constitutive tyrosine phosphorylation of one of the two SLP-65 isoforms and complex
formation between SLP-65 and the protooncoprotein CrkL (CT10 regulator of kinase like).
This leads to antigen receptor-independent phosphorylation of Cbl (Casitas B lineage lym-
phoma) and C3G. In contrast, phospholipase C-
 
 
 
2 (PLC-
 
 
 
2) activation is completely blocked.
Our data show that in order to establish a latent EBV infection, LMP2A selectively activates or
represses SLP-65–regulated signaling pathways.
 
Key words: B lymphocytes • Epstein-Barr virus • antigen receptor • SLP-65 • signal transduction
 
Introduction
 
EBV is an oncogenic herpes virus that infects human B
lymphocytes through attachment to the CD21 surface
marker (for a review, see references 1 and 2). EBV is the
causative agent of infectious mononucleosis and is associ-
ated with numerous malignancies including Burkitt’s lym-
phoma, Hodgkin’s disease, and nasopharyngeal carcinoma.
Like all herpes viruses, EBV is able to persist in infected
cells in a latent form. Only a few virally encoded proteins
are expressed in EBV-positive peripheral B cells, such as
the EBV-associated nuclear antigen (EBNA)
 
*
 
 1 and the in-
tegral latent membrane protein 2A (LMP2A). Infection of
B cells in vitro results in expression of additional EBNAs
together with LMP1, and an LMP2A splice variant,
LMP2B (3). These B cells become immortalized and are
called lymphoblastoid cell lines (LCLs). EBNAs are in-
volved in maintaining the viral genome and, together with
LMP1, are required for EBV-mediated B cell transforma-
tion. It is the expression of LMP2A that regulates EBV la-
tency by remodeling signal transduction events from the B
cell antigen receptor (BCR; references 4–8).
In the absence of antigen, a yet poorly understood BCR
maintenance signal drives B cells through developmental
checkpoints and is indispensable for the survival of mature,
peripheral B cells (9–11). Antigen engagement triggers a
BCR activation signal that allows proliferation and poten-
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Abbreviations used in this paper:
 
 BCR, B cell antigen receptor; BLNK,
B cell linker protein; Btk, Bruton’s tyrosine kinase; Cbl, Casitas B lineage
lymphoma; Crk, CT10 regulator of kinase; CrkL, Crk like; EBNA,
EBV-associated nuclear antigen; GST, glutathione 
 
S
 
-transferase; ITAM,
immunoreceptor tyrosine-based activation motif; LCL, lymphoblastoid
cell line; LMP2A, latent membrane protein 2A; PLC-
 
 
 
2, phospholipase
C-
 
 
 
2; PTK, protein tyrosine kinase; pTyr, phosphotyrosine; RAG, re-
combination activating gene; SLP, SH2 domain-containing leukocyte
protein; SH2, Src homology 2 domain; WT, wild-type. 
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tially differentiation of stimulated B cells into antibody-
secreting plasma cells (12–14). Both BCR functions are de-
pendent on the immunoreceptor tyrosine-based activation
motif (ITAM) in the BCR signaling elements, Ig-
 
 
 
 and Ig-
 
 
 
,
and on cytoplasmic protein tyrosine kinases (PTKs) of
the Src-, Syk-, and Tec families. An immediate early sub-
strate of Syk is the Src homology 2 (SH2) domain-contain-
ing leukocyte adaptor protein (SLP)-65 (15), (also called B
cell linker protein [BLNK; reference 16] or B cell adaptor
containing SH2 domain [BASH; reference 17]). SLP-65
contains at least five consensus tyrosine-phosphorylation
sites at the N terminus, followed by several putative bind-
ing motifs for SH3 domains and a COOH-terminal SH2
domain. Phosphorylated SLP-65 couples Syk and the Tec
family member Bruton’s tyrosine kinase (Btk) to phosphor-
ylation and hence activation of phospholipase C-
 
 
 
2 (PLC-
 
 
 
2; references 16 and 18–21). This triggers the mobiliza-
tion of intracellular Ca
 
2
 
 
 
 ions, which is a hallmark of the
BCR activation signal (22). Mutations in BCR compo-
nents or BCR effector proteins impair the development
and activation of B cells in mouse and man (9, 23–26). This
is also true for loss of SLP-65 expression. SLP-65 knockout
mice have been generated by multiple groups (27–30) and
show a drastic reduction in the number of mature B cells
due to a block at the transition from B220
 
 
 
CD43
 
 
 
 pro-
genitor B (proB) to B220
 
 
 
CD43
 
 
 
 precursor B (preB) cells.
A small number of IgM
 
hi
 
 B cells are seen in peripheral im-
mune organs; however, mature IgM
 
lo
 
IgD
 
hi
 
 are not.
LMP2A is anchored in the plasma membrane by 12 hy-
drophobic membrane spanning regions and assembles into
large aggregates (4) within glycolipid-enriched micro-
domains, so-called lipid-rafts or glycosphingolipid-enriched
membrane microdomains (GEMs; reference 31). The ter-
mini are facing the cytosol and consist of 119 and 27 amino
acids, respectively. LMP2A redirects BCR signaling in two
ways. First, the constitutively phosphorylated ITAM ty-
rosines in the NH
 
2
 
-terminus of LMP2A recruit Syk via the
PTK’s Src homology (SH)2 domains (32, 33). Similarly,
Src family PTKs like Lyn and Fyn are sequestered by
LMP2A (34, 35) and therefore cannot be employed by the
BCR to trigger an activation signal. As a consequence,
LMP2A expression renders B cells largely unresponsive to
BCR ligation by antigen in that they fail to induce PTK
substrate phosphorylation and subsequent mobilization of
Ca
 
2
 
 
 
 ions (5–8). This signaling block prevents a BCR-
induced lytic production of EBV particles and thereby
contributes to a successful escape of the virus from immune
recognition. Beside the dominant-negative effect on the
BCR signaling machinery, a second function of LMP2A
was initially suggested by the finding that its isolated
ITAM-containing terminus can mimic BCR signaling
events when expressed and ligated as a CD8 chimera (36,
37). The in vivo role of this positive LMP2A signaling ca-
pacity has been recently demonstrated in the E
 
 
 
LMP2A
transgenic mouse line E (TgE) with B cell lineage expres-
sion of LMP2A (38). TgE mice show a dramatic reduction
in the number of BCR-positive B cells present in develop-
ing bone marrow and peripheral immune organs. Despite
 
the absence of a cognate BCR, TgE B cells are capable of
progressing out of the bone marrow and entering the pe-
ripheral immune system where they persist. This is in sharp
contrast to wild-type (WT) mice, where these immunolog-
ically useless cells become rapidly eliminated by apoptosis
(9). The lack of surface BCR expression on TgE B cells
was found to be due to a block of Ig heavy chain gene rear-
rangement during B cell development (38). The results
show that LMP2A provides B cells with a survival signal
that can substitute the BCR maintenance signal to bypass
normal developmental checkpoint controls. The molecular
details underlying the BCR or LMP2A maintenance signal
are not known to date. In this report we show that LMP2A
signals B cell survival through the p70 isoform of human
SLP-65 and the protooncogene product CT10 regulator of
kinase like (CrkL).
 
Materials and Methods
 
Generation and Analysis of Transgenic Mice.
 
Construction and
characterization of SLP-65/BLNK
 
 
 
/
 
 
 
 mice (B6.129F1 back-
ground) and E
 
 
 
LMP2A transgenic animals have been described
previously (27, 38). E
 
 
 
LMP2A transgenic line E (TgE) mice
have been bred for over 10 generations into the C57BL/6 back-
ground. TgE males were mated with SLP-65
 
 
 
/
 
 
 
 females to ob-
tain F1 progeny. F1 progeny were further mated to obtain trans-
genic LMP2A SLP-65
 
 
 
/
 
 
 
 mice. All animals were housed at the
Northwestern University Center for Experimental Animal Re-
sources in accordance with university animal welfare guidelines.
Isolation of tail DNA and polymerase chain reaction for the pres-
ence of the LMP2A transgene, recombination activating gene
(RAG)-1, and the Neomycin cassette was done as described pre-
viously (38–40). Presence of the SLP-65/BLNK gene was deter-
mined by PCR using the primers BLNK sense (5
 
 
 
-GGACAAA-
CAGGAAGTAGTG-3
 
 
 
) and BLNK antisense (5
 
 
 
-CTGGCA-
GGGACAGTTATC-3
 
 
 
). Flow cytometry analysis of B cell
populations was done as described previously (38–40) using anti-
bodies purchased from BD PharMingen. Samples were run on a
Becton Dickinson FACScan™ and data was analyzed using
CELLQuest™ software.
 
Cell Culture.
 
LCLs were generated by infection of peripheral
IgM- and IgG-positive B cells from healthy human donors with
EBV strain B95-8 and maintained, like the EBV-negative Ramos
B cell line (41) in RPMI 1640 supplemented with 10% fetal calf
serum, 2 mM glutamine, 100 IU/ml penicillin, and 100
 
 
 
 
 
g/ml
streptomycin at 37
 
 
 
C and 5% CO
 
2
 
. LCLs used in this study (BS,
DK, NB, and OP) are heterogeneous for surface expression of
IgM, IgD, and IgG. Surface IgM expression of LCL-BS was
higher than that of Ramos B cells, while that of LCL-DK, LCL-
DU, LCL-NB, and LCL-OP was reduced, and these cells be-
came IgM-negative after a long time in culture. Stimulation of
the cells with either F(ab
 
 
 
)
 
2
 
 fragments of anti-Ig antibodies or
pervanadate/H
 
2
 
O
 
2
 
 has been described elsewhere (42–44).
 
Protein Isolation and Analysis.
 
After lysis of the unstimulated
or stimulated B cells in 1% Nonidet P-40 buffer (44), immuno-
precipitations were performed using agarose-coupled mouse
monoclonal antibodies to phosphotyrosine (pTyr; 4G10; UBI),
or with protein G-adsorbed mouse monoclonal antibodies to hu-
man SLP-65/BLNK (Babco), or with rabbit antibodies specific
for the following BCR effector proteins: PLC-
 
 
 
2 (Q20), CrkL,
and C3G (Santa Cruz Biotechnology, Inc.); and Casitas B lineage 
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lymphoma (Cbl; Transduction Laboratories/Becton Dickinson).
Mouse monoclonal anti-CrkL (UBI) and anti-Syk (4D10; Santa
Cruz Biotechnology, Inc.) were used for protein detection by
immunoblot analysis. The fusion protein between the glutathione
 
S
 
-transferase (GST) and the tandem SH2 domains of Syk, and its
application for affinity purification of phosphoprotein ligands are
described in detail elsewhere (42–44).
 
Results
 
The Adaptor SLP-65/BLNK Is a Critical Downstream Effec-
tor of LMP2A.
 
The phenotype of TgE mice demon-
strated that LMP2A is capable of altering normal B cell
development and enhancing survival in vivo (38). Biochemi-
cal studies in LCLs revealed that this LMP2A function is
dependent on its ITAM which becomes tyrosine phosphor-
ylated and binds Syk (7, 8, 32, 33). This suggested a role
for the SLP-65 adaptor protein in initiating LMP2A-medi-
ated signals, as SLP-65 is an early and specific Syk substrate
(15, 16). To test whether loss of SLP-65 affects LMP2A
function in vivo, SLP-65/BLNK-deficient animals (de-
scribed in reference 27) were bred to TgE mice. Spleen
and bone marrow samples isolated from WT, TgE, SLP-
65
 
 
 
/
 
 
 
, and TgE SLP-65
 
 
 
/
 
  
 
animals were analyzed by flow
cytometry (Fig. 1). Cells were stained with antibodies to
the pan-B cell marker CD19 and IgM and relative percent-
ages of the different B cell populations were calculated
based on a lymphocyte gate. As expected, WT animals
showed the normal pattern of B cell development consist-
ing of CD19
 
 
 
IgM
 
 
 
 B cells (48 
 
  
 
7%) developing into
CD19
 
 
 
IgM
 
 
 
 B cells (25 
 
 
 
 7%) in the bone marrow. These
WT CD19
 
 
 
IgM
 
 
 
 cells colonize peripheral immune or-
gans, such as the spleen, where most B cells display a
CD19
 
 
 
IgM
 
 
 
 phenotype (61 
 
 
 
 7%) with variable levels of
IgM surface expression. In contrast, TgE animals show the
LMP2A phenotype with most developing bone marrow B
cells displaying a CD19
 
 
 
IgM
 
 
 
 phenotype (62 
 
 
 
 9%) and a
very low number of B cells being CD19
 
 
 
IgM
 
 
 
 
 
(1 
 
 
 
 1%).
TgE CD19
 
 
 
IgM
 
 
 
 B cells exit the bone marrow and colo-
nize the spleen (14 
 
 
 
 5%). SLP-65
 
 
 
/
 
 
 
 animals display the
expected phenotype of a block in B cell development from
the pro-B to pre-B stage showing a small number of
CD19
 
 
 
IgM
 
 
 
 B cells in the bone marrow (9 
 
 
 
 1%) and the
spleen (9 
 
 
 
 2%). As observed previously, a small popula-
tion of IgM
 
hi
 
 B cells accumulates over time in SLP-65
 
 
 
/
 
 
 
mice (27). TgE SLP-65
 
 
 
/
 
 
 
 animals were indistinguishable
from SLP-65
 
 
 
/
 
 
 
 animals with respects to B cell develop-
ment. TgE SLP-65
 
 
 
/
 
 
 
 bone marrow B cells were identi-
fied as being either CD19
 
 
 
IgM
 
  
 
B cells (43 
 
  
 
5%) or
CD19
 
 
 
IgM
 
 
 
 B cells (6 
 
 
 
 1%). Similarly to SLP-65
 
 
 
/
 
 
 
mice, TgE SLP-65
 
 
 
/
 
  
 
animals have a small number of
CD19
 
 
 
IgM
 
 
 
 B cells in the spleen (6 
 
 
 
 2%). Flow cyto-
metric analysis of B220, CD19, and CD43 expression in
bone marrow samples from TgE SLP-65
 
 
 
/
 
  
 
mice and SLP-
65
 
 
 
/
 
 
 
 littermate controls further confirmed that both ani-
mals display an almost identical block of B cell develop-
ment, i.e., at the pre-BI (B220
 
 
 
CD19
 
 
 
CD43
 
 
 
) to pre-BII
(B220
 
 
 
CD19
 
 
 
CD43
 
 
 
) stage (data not shown). Similar re-
sults were obtained from another LMP2A transgenic line
displaying a weaker phenotype (Tg6) when bred into the
SLP-65
 
 /  background (data not shown). These results
show that LMP2A is incapable of transmitting signals to al-
ter B cell development and survival in vivo in the absence
of SLP-65. The possibility that SLP-65 could be necessary
Figure 1. Loss of the LMP2A developmental and survival phenotype when bred into the SLP-65 /  background. (A) Mouse splenocytes (SP) and (B)
bone marrow samples (BM) from WT, TgE SLP-65 / , and TgE SLP-65 /  animals were subjected to flow cytometric analysis with at least 10,000
gated lymphocytes collected per animal using CD19-PE (CD19) and IgM-FITC (IgM) antibodies. Typical dot plot results of 10,000 gated lymphocytes
from 5–7-wk-old animals (n   5) are shown. The polygons represent distinct subpopulations of B cells with the average percentage of total gated lym-
phocytes indicated above each polygon. (A) The left polygon represents CD19 IgM  B cells typical in TgE animals; the right polygon represents
CD19 IgM  cells. (B) The left rectangle represents CD19 IgM  B cells; the right rectangle represents CD19 IgM  B cells.258 LMP2A Signals through SLP-65/BLNK
for the differentiation of an EBV target population that will
be subsequently driven by LMP2A signals can be excluded,
as LMP2A expression in RAG-1–deficient animals (TgE
RAG-1 / ) releases the block of pro-B cell development
(38). Thus, early pro-B cells are already susceptible to
LMP2A signaling, but this developmental stage is not af-
fected by the loss of SLP-65 (27–30).
LMP2A Triggers Constitutive Tyrosine Phosphorylation of
Syk and SLP-65. To biochemically analyze LMP2A sig-
naling pathways and to address the role of SLP-65 in more
detail several independent LCLs were established. As
shown in Fig. 2 and in line with previous reports (7, 32–
35), our LCLs express the 53-kD LMP2A, which is consti-
tutively phosphorylated on its ITAM tyrosines. The latter
feature allows LMP2A to be specifically purified with a
GST fusion protein encompassing the tandem SH2 do-
mains of Syk and to be detected by anti-pTyr immunoblot-
ting (Fig. 2 A, lanes 1–4). P53 is absent in the preparation
from LMP2A-negative Ramos B cells (lanes 5 and 6). In
this case, the Syk SH2 domains purify tyrosine-phosphory-
lated Ig-  after BCR activation of the cells. The results
confirm that the previously published association between
tyrosine-phosphorylated LMP2A and Syk (7, 32, 33) is me-
diated by the Syk SH2 domains, which possess an exquisite
binding specificity for doubly phosphorylated ITAMs (42).
The lack of tyrosine-phosphorylated Ig-  in stimulated
LCLs (lanes 2 and 4) directly shows the LMP2A-mediated
inhibition of BCR signal transduction (5–8). This is further
demonstrated by anti-pTyr immunoblot analysis of LCLs
(Fig. 2 B, top panel). In addition to LMP2A, a second ma-
jor phosphoprotein of 70 kD (p70) can be detected (lanes
1–6). The intensity of all protein bands is independent of
BCR engagement. Moreover and in marked contrast to
EBV-negative Ramos B cells (lanes 7–9), BCR engage-
ment on LCLs does not increase the complexity of the
pTyr-containing protein pattern. In summary, the LCLs
used in this study show the same features than those previ-
ously employed for the analysis of LMP2A function (5–8).
As reported by Miller et al. (7), the p70 phosphoprotein
band of LCLs is recognized by anti-Syk antibodies (Fig. 2
B, middle panel, lanes 1–6). However, repeated preclearing
with anti-Syk antibodies failed to completely remove this
band from anti-pTyr immunoprecipitates (data not shown).
Probing of the same material with anti-SLP-65 antibodies
revealed that anti-pTyr precipitates from unstimulated and
stimulated LCLs also contain SLP-65 (Fig. 2 B, bottom
panel, lanes 1–6). As for Syk, detection of SLP-65 in anti-
pTyr precipitates from Ramos B cells required BCR liga-
tion (lanes 7–9). However, whereas both SLP-65 isoforms,
p68 and p70, are present in the preparation from activated
Ramos B cells, predominantly the slower migrating form is
detected in anti-pTyr precipitates from LCLs. Both iso-
forms are expressed by LCLs to similar amounts (Fig. 2 C).
To directly test for tyrosine phosphorylation of SLP-65 in
LCLs, anti–SLP-65 precipitates were analyzed by anti-pTyr
immunoblotting. As shown in Fig. 3, the p70 isoform of
purified SLP-65 from LCLs is constitutively tyrosine phos-
phorylated (lanes 1–4). In Ramos B cells, both SLP-65 iso-
Figure 2. Impaired BCR signaling but elevated levels of pTyr-contain-
ing proteins in EBV-infected B cells. Two independently obtained LCLs
(lanes 1–4 in panel a and 1–6 in panel b) and EBV-negative Ramos B
cells (lanes 5 and 6 in panel a and 7–9 in panel b) were left untreated or
stimulated through their BCR with F(ab )2 fragments of anti-IgM anti-
bodies for the indicated time points (30 s or 3 min). (a) From the cleared
cellular lysates, phosphoproteins were isolated by affinity purification (AP)
with a GST fusion protein encompassing the tandem SH2 domains of Syk
(GST-SYK[SH2]2) and detected by anti-pTyr immunoblotting. (b) Ly-
sates were subjected to immunoprecipitation (IP) with anti-pTyr antibod-
ies and the material was analyzed by subsequent immunoblotting with an-
tibodies to pTyr (top panel), Syk (middle panel), and SLP-65 (bottom
panel). (c) Cellular lysates of the different LCLs used in this study (lanes
1–4) and Ramos B cells (lane 5) were immunoblotted with anti–SLP-65
antibodies. Relative molecular masses of marker proteins are indicated on
the left in kD.259 Engels et al.
forms become inducibly phosphorylated (lanes 5 and 6).
Collectively, our data establish that EBV infection triggers
constitutive tyrosine phosphorylation of the 70-kD form of
human SLP-65.
In LCLs, the Syk/SLP-65 Complex Is Uncoupled from
PLC- 2 Activation. SLP-65 has been shown to be a spe-
cific substrate of activated Syk (16). Consistent with this,
we find that Syk and SLP-65 coimmunoprecipitate after
BCR ligation of Ramos B cells (Fig. 4, lanes 5 and 6). In
LCLs, however, this association is stimulation independent,
which explains why SLP-65 is constitutively phosphory-
lated in these cells (Fig. 4, lanes 1–4). A direct downstream
effector protein of phosphorylated SLP-65 is PLC- 2,
which upon dual phosphorylation by Syk and Btk initiates
mobilization of Ca2  ions (16, 18–21). In activated Ramos
B cells, PLC- 2 is tyrosine phosphorylated and coimmu-
noprecipitates with phosphorylated SLP-65 (Fig. 5, lanes 7
and 8). PLC- 2 isolated from unstimulated or stimulated
LCLs remains almost unphosphorylated (Fig. 5, top panel,
lanes 1–6). In some LCLs, a weak association between
PLC- 2 and SLP-65 could be observed (Fig. 5, middle
panel, lanes 4–6). The results demonstrate that EBV infec-
tion uncouples phosphorylation of Syk and SLP-65 from
PLC- 2 activation. The underlying mechanism for this
phenomenon remains to be elucidated but the data provide
an explanation for the described block of BCR-induced
Ca2  mobilization in LMP2A-expressing B cells (5). More-
over, our data suggest that in these cells, SLP-65 may be
indirectly translocated to the plasma membrane by virtue of
its association with phosphorylated Syk bound to the phos-
pho-ITAM of LMP2A.
Constitutive SLP-65 Phosphorylation in LCLs Is Accompa-
nied with a Constant Trigger of the CrkL-Cbl-C3G Path-
way. The 38-kD intracellular adaptor protein CrkL con-
sists of one SH2 and two SH3 domains and has been
implicated in positive and negative regulation of lympho-
cyte proliferation (45–49). The coimmunoprecipitation
experiment shown in Fig. 6 A (top panel) identifies CrkL
as a novel SLP-65–binding protein in vivo. The p68 and
p70 isoforms of SLP-65 are detected in anti-CrkL precipi-
tates from stimulated and weakly from unstimulated Ra-
mos B cells (lanes 5 and 6). Also in anti-CrkL precipitates
from LCLs, both SLP-65 isoforms are present but their de-
tection is not regulated by BCR engagement (lanes 1–4).
SLP-65 could not be detected in anti-Crk II precipitates
(data not shown). These data show that EBV infection
causes a constitutive complex formation between SLP-65
and the protooncogene product CrkL. The presence of the
68-kD isoform of SLP-65 in anti-CrkL precipitates from
LCLs shows that the association is at least in part indepen-
dent of SLP-65 phosphorylation and hence may involve
the CrkL SH3 domain(s).
The SH2 and central SH3 domain of CrkL are known to
bind the Fyn-associated ubiquitin ligase Cbl and the Rap1-
specific guanine nucleotide exchange factor C3G (45–47,
Figure 3. Constitutive tyrosine phosphorylation of the p70 isoform of
SLP-65 in EBV-infected B cells. Two independent LCL clones (lanes 1–4)
and Ramos B cells (lanes 5 and 6) were left untreated (lanes 1, 3, and 5) or
stimulated through their BCR for 3 min (lanes 2, 4, and 6). From the
cleared lysates of these cells, anti–SLP-65 immunoprecipitates (IP) were
prepared and analyzed by anti-pTyr immunoblotting. Relative molecular
mass of marker protein is indicated on the left in kD.
Figure 4. Syk and SLP-65 associate in vivo. Anti–SLP-65 immunopre-
cipitates from unstimulated and BCR-stimulated LCLs (lanes 1–4) or Ra-
mos B cells (lanes 5 and 6) were analyzed by anti-Syk immunoblotting.
Relative molecular mass of marker protein is indicated on the left in kD.
Note that a constitutive Syk/SLP-65 complex formation was observed in
all LCLs that have been investigated (n   4), but some variability in the
amount of Syk present in SLP-65 immunoprecipitates was observed
(compare lanes 1 and 4).
Figure 5. Block of PLC- 2 phosphorylation in LCLs. Anti–PLC- 2
immunoprecipitates from unstimulated and BCR-stimulated LCLs (lanes
1–6) or Ramos B cells (lanes 7 and 8) were analyzed by immunoblotting
with antibodies to pTyr (top panel), SLP-65 (middle panel), or PLC- 2
(bottom panel). Relative molecular masses of marker proteins are indi-
cated on the left in kD.260 LMP2A Signals through SLP-65/BLNK
50–53). Consistent with previous reports we find an in-
creased association of CrkL with Cbl after BCR ligation of
Ramos B cells (Fig. 6A, middle panel, lanes 5 and 6). The
amount of Cbl that co-immunoprecipitates with CrkL
from two LCLs (lanes 1–4) is almost independent of BCR
stimulation in that only a slight increase of complex forma-
tion is observed in only one of the two lines (lanes 1 and 2).
Similarly, CrkL and C3G coimmunoprecipitate from LCL
lysates independent of cellular stimulation (Fig. 6 A, bot-
tom panel, lanes 1–4). After BCR ligation of Ramos B
cells, a slight decrease of the anti-C3G signal was observed
in some but not in all experiments (lanes 5 and 6). Fig. 6 B
shows that CrkL and C3G are inducibly phosphorylated in
Ramos B cells (lanes 5 and 6), but are constitutively phos-
phorylated in LCLs (lanes 1–4). In summary, this set of ex-
periments revealed that LMP2A expression affects not only
the phosphorylation status of the p70 SLP-65 isoform but
also abolishes the requirement of BCR ligation for a phos-
phorylation-dependent complex formation to CrkL. The
CrkL-Cbl-C3G signaling module seems to be permanently
triggered in LCLs.
LCLs Are Unresponsive to Pervanadate/H2O2 Treatment.
To further compare the signaling behavior between EBV-
positive and -negative B cells, LCLs and Ramos B cells
were treated with the protein tyrosine phosphatase inhibi-
tor pervanadate/H2O2. Subsequently, pTyr-containing pro-
teins were purified with anti-pTyr antibodies. As reported
for many cell types, pervanadate/H2O2 treatment of Ra-
mos B cells changes the equilibrium between dephosphor-
ylation and phosphorylation towards the latter and hence
induces robust PTK substrate phosphorylation (Fig. 7, top
panel, lanes 5 and 6). Unexpectedly, all LCLs tested in this
assay were unresponsive in that no pervanadate-mediated
increase of protein tyrosine phosphorylation could be ob-
served (top panel, lanes 1–4). Probing of the filter with
anti-Syk (middle panel) and anti–SLP-65 antibodies (bot-
tom panel) showed that both signaling proteins could be
purified to similar amounts from untreated and pervana-
date-treated LCLs (lanes 1–4). In contrast, efficient anti-
pTyr immunoprecipitation of Syk and SLP-65 from
Ramos B cells required incubation of the cells with per-
vanadate/H2O2 (lanes 5 and 6). Pervanadate/H2O2 induces
not only Syk- or Lyn-specific protein phosphorylation that
can be affected by LMP2A. Hence, the data show for the
first time that EBV infection renders B cells not only unre-
sponsive to BCR activation but generally abrogates their
ability to induce PTK substrate phosphorylation. Whether
this is solely mediated by LMP2A remains to be elucidated.
Figure 6. Association of the protooncoprotein CrkL with SLP-65. (a)
Anti-CrkL immunoprecipitates (IP) were prepared from cleared cellular
lysates of untreated or BCR-stimulated LCLs (lanes 1–4) and Ramos B
cells (lanes 5 and 6), and analyzed by subsequent immunoblotting with
antibodies to SLP-65 (top panel), Cbl (middle panel), and C3G (bottom
panel). (b) Anti-pTyr immunoprecipitates from the same cells were ana-
lyzed by anti-CrkL or anti-C3G immunoblotting (top and bottom panel,
respectively). Relative molecular masses of marker proteins are indicated
on the left in kD.
Figure 7. EBV-positive B cells are unresponsive to treatment with per-
vanadate/H2O2. Two independent LCL clones (lanes 1–4) and Ramos B
cells (lanes 5 and 6) were left untreated (lanes 1, 3, and 5) or incubated
with 20  M pervanadate/H2O2 for 3 min at 37 C (lanes 2, 4, and 6).
From the cleared cellular lysates, tyrosine-phosphorylated proteins were
purified by immunoprecipitation (IP) and analyzed by subsequent immu-
noblotting with antibodies to pTyr (top panel), Syk (middle panel), and
SLP-65 (bottom panel). Relative molecular masses of marker proteins are
indicated on the left in kD.261 Engels et al.
Discussion
LMP2A reorganizes BCR-regulated survival and activa-
tion in EBV-infected B cells (5–8, 32, 33, 38). Recent bio-
chemical and genetic evidence identified the adaptor SLP-
65 as a central BCR effector protein downstream of Syk
(15–21, 27–30, 54). Here we have shown that loss of SLP-
65 expression abrogates LMP2A-mediated signaling for B
cell development and survival in vivo. Analysis of human
LCLs provided insight into the molecular mechanism(s) of
this phenotype. EBV infection of B cells causes constitutive
tyrosine phosphorylation of human SLP-65, primarily of its
p70 isoform. Other B cell signaling proteins, such as Ig- 
or the SLP-65 effector protein PLC- 2, remain unphos-
phorylated even after BCR ligation. Another novel finding
is the association of SLP-65 with CrkL, which is regulated
by the BCR in normal B cells but not in LCLs. Finally, we
have demonstrated that after EBV infection, not only
BCR-specific signal transduction but also pervanadate/
H2O2-induced PTK substrate phosphorylation is rescinded.
Hence, LMP2A expression seems to broadly inhibit the
ability of cellular PTKs to respond to cellular stimulation.
As a consequence, EBV infection may inhibit ligand-induced
signaling from many surface receptors that transmit their
activation signal through cellular PTKs. One mechanism to
achieve this function might be related to the constitutive
targeting of LMP2A into lipid-rafts (31). This may create a
microenvironment, which prevents translocation of the ac-
tivated BCR as well as of other stimulated receptors into
the signaling-competent membrane compartment. Experi-
ments are under way to test this directly.
After B cell activation, one of the earliest Syk substrates
is the cytoplasmic adaptor protein SLP-65 (15, 16, 43, 55).
In line with this, we found that Syk and SLP-65 coimmu-
noprecipitate from lysates of BCR-stimulated Ramos B
cells. The stimulation-independent association between
Syk and SLP-65 observed in LCLs explains the constitutive
SLP-65 phosphorylation in these cells. As described previ-
ously, efficient coupling between Syk and SLP-65 is orga-
nized by the BCR and Y→F substitutions in the Ig- 
ITAM reduce SLP-65 phosphorylation (43, 55). The data
presented here suggest that LMP2A can substitute this
BCR function. Consistent with this, two of the eight ty-
rosine residues in the N terminus of LMP2A are organized
as an ITAM (56), which is essential for LMP2A function in
vitro and in vivo (33, 40).
Lack of SLP-65 expression leads to a partial block of B
cell development in mice and to a complete absence of ma-
ture B cells in a patient suffering from severe antibody defi-
ciency (27–30, 54). A nearly identical phenotype is caused
by mutations in the btk gene, which lead to X-linked im-
munodeficiency (XID) in mice and X-linked agammaglob-
ulinemia (XLA) in humans (25, 57, 58). These results sug-
gest that SLP-65 and Btk function in a common BCR
signaling pathway. In support of this, phosphorylated SLP-
65 recruits both, PLC-  (16, 18, 19) and Btk (20, 21)
through their SH2 domains. These are critical events for
the phosphorylation and activation of PLC-  allowing the
subsequent generation of second messenger (for reviews,
see references 14 and 22). In our LCLs, phosphorylation of
PLC- 2 is not detectable, despite the prominent and con-
stitutive phosphorylation of Syk and SLP-65. At present we
can only speculate about the mechanism that is responsible
for this signaling block, but it may involve an LMP2A-reg-
ulated structural organization of proteins that prevents the
interaction between PLC- 2 and the SLP-65 signaling
module. Possibly, LMP2A expression excludes PLC- 2
from entry into lipid-rafts.
In human B cells, the primary slp-65 transcript is alterna-
tively spliced generating the 68-kD and the 70-kD SLP-65
isoforms (16). Interestingly, p68 lacks amino acids 201–225
of p70, which encompass a putative binding motif for SH3
domains. Whether p68 and p70 perform different BCR sig-
naling functions is not known. The selective and constitu-
tive phosphorylation of p70 in LCLs together with the phe-
notype of TgE SLP-65 /  mice strongly suggest a dominant
role of this SLP-65 isoform for the LMP2A-mediated B cell
maintenance signal and probably also for the BCR mainte-
nance signal. From our data, however, it is not completely
clear whether the CrkL-Cbl-C3G pathway downstream of
SLP-65 is involved in signaling cell survival or whether it is
involved in establishing B cell anergy that renders EBV-
infected B cells unresponsive to BCR ligation. Of the three
known Crk isoforms (I, II, and L), particularly CrkL is
known to transmit signals from lymphocyte antigen recep-
tors (45–47). A positive signaling function of CrkL is sug-
gested by its capacity to transform cells when mutated or
overexpressed, and by the finding that CrkL is the dominant
phosphoprotein in v-Abl–transformed pre-B cells (49, 59).
CrkL may also participate in negative regulation of lympho-
cytes through its SH2-mediated binding to the ubiquitin li-
gase Cbl (51, 52). The constitutive phospho-Cbl/CrkL
complex in LCLs could play a role in the ubiquitination-
mediated degradation of signaling proteins. Indeed, three
Nedd4-like ubiquitin ligases were recently found to directly
associate with LMP2A (60, 61). Moreover, the structurally
unusual SH2 domain of Cbl competes with PLC- 2 for
binding to phosphorylated SLP-65 (62), which could also
contribute to the observed block of PLC- 2 phosphoryla-
tion in our LCLs. In anergic T cells, which do not transcribe
the Il-2 gene upon TCR activation, constitutive phos-
phorylation of Cbl leads to assembly of a ternary Cbl-CrkL-
C3G complex that activates the Rap1 pathway independent
of TCR ligation (48, 53). Overexpression of activated Rap1
in Jurkat cells recapitulated T cell anergy. The constitutive
association of Cbl with CrkL and C3G in LCLs suggests that
a similar pathway could operate in EBV-infected B cells to
block BCR-mediated activation of the cells. The BCR can
activate Rap1 via a PLC- –dependent pathway, which may
be independent of CrkL and C3G (63).
In EBV-negative B cells, the SLP-65/CrkL complex is
regulated by the BCR, indicating that phosphorylated
SLP-65 is bound by the CrkL SH2 domain. Consistent
with this, the four YXXP phosphorylation motifs of SLP-262 LMP2A Signals through SLP-65/BLNK
65 are nearly identical to those found in known CrkL-
binding proteins such as Cas (Crk-associated substrate) and
Cbl. Similar amino acid sequences were selected by the
CrkL SH2 domain from a phosphopeptide library (64).
The finding that in LCLs, also the nonphosphorylated p68
isoform of SLP-65 coprecipitates with CrkL, suggests a
function for the CrkL SH3 domain(s). At least seven PXXP
consensus binding sites for SH3 domains are present in
SLP-65 and a low level of SLP-65/CrkL complexes was
repeatedly found in unstimulated Ramos B cells. We there-
fore conclude that the CrkL-derived SH2 and SH3 do-
mains synergistically regulate the interaction with SLP-65
in resting and activated B cells.
In summary, our analysis revealed several novel aspects
of LMP2A-mediated reorganization of B cell signaling ele-
ments. While a stimulation-dependent PTK substrate
phosphorylation becomes generally suppressed, certain sig-
naling pathways emanating from the SLP-65 module are
selectively activated to keep EBV infected cells alive. Fu-
ture studies on the assembly and function of the BCR or
LMP2A signalosome will be required to better understand
B lymphopoiesis and to finally interfere with it in patho-
logical situations.
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